Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
How Technology Is Changing the Way We Look at Health Data, & How Patients Are Critical to Its Success
Pete Knox represents The Life Raft Group and GIST patients at ISPOR’s 2019 European Conference, held November 2nd-6th in Copenhagen, Denmark.
Pete Knox's presentation on current and emerging medications for GIST.
The Ottawa GIST Day of Learning (GDOL) was hosted by the Life Raft Group Canada and the LRG's Pete Knox presented on SideEQ virtually.
The Future of RWE & Improving the Quality of Patient Survival Two members of The LRG staff recently attended the annual ISPOR meeting in New Orleans. ISPOR (International Society for Pharmaceutical Economics and Outcomes [...]
What Can SideEQ Do for You? What is personalized side effect management, and why is it important for your survival and quality of life? “Never judge a person until you’ve walked a mile in [...]
Ten Tips for Life with a Rare Disease The challenges of living with GIST are many - here are our top ten tips to navigate this journey toward thriving and surviving. 1. Get a [...]
Left to right: Laura Occhiuzzi, Pete Knox, Alyssa O’Driscoll, Sarcoma Alliance, Annie Achee, National LeioMyoSarcoma Foundation, Denise Reinke, SARC, and Mitch Achee, National LeioMyoSarcoma Foundation. GIST Research from CTOS 2018 A web-based [...]
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]